论文部分内容阅读
目的 为应用胶体Cr~(32)PO_4治疗肝癌提供剂量依据。方法 将接种Hep—A—22肝癌瘤株后9天的小鼠,按每立方厘米瘤体积注射不同剂量的胶体Cr~(32)PO_4,分别在治疗后7天,15天,24天测量肿瘤大小,观察生存期。结果 在37MBq/cm~3和18.5MBq/cm~3两组疗效明显,并明显小于用药前肿瘤体积,生存期明显延长。两组均有60％荷瘤鼠已无肉眼可见瘤块。结论 肿瘤局部注入胶体Cr~(32)PO_4对某些实体瘤确实是一种有效的疗法,最佳剂量范围应在37MBq/cm~3至18.5MDQ/cm~3之间。
Objective To provide dose basis for the treatment of liver cancer with colloidal Cr 32 PO 4 . Methods After injection of Hep-A-22 tumor-bearing tumor strains for 9 days, mice were injected with different doses of colloidal Cr32PO4 per cubic centimeter of tumor volume. Tumors were measured at 7 days, 15 days, and 24 days after treatment. Size, observe the survival period. Results The curative effect was obvious in 37MBq/cm~3 and 18.5MBq/cm~3 groups, and it was significantly smaller than that before treatment. The survival time was significantly prolonged. In both groups, 60% of tumor-bearing mice had no visible masses. Conclusion The injection of colloidal Cr 32 PO 4 into tumors is indeed an effective therapy for certain solid tumors. The optimal dose range should be between 37 MBq/cm~3 and 18.5 MDQ/cm~3.